Long-term durability and dose escalation patterns in infliximab therapy for psoriasis

Journal of the American Academy of Dermatology

Volumn 70, Issue 3, 2014, Pages 525-532

  Luber, Adam J ^a   Tsui, Cindy L ^a   Heinecke, Gillian M ^a   Lebwohl, Mark G ^a   Levitt, Jacob O ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

anti infliximab antibodies; dose escalation; dose intensification; human antichimeric antibodies; infliximab; methotrexate; psoriasis

Indexed keywords

ANTI-INFLIXIMAB ANTIBODIES; DOSE ESCALATION; DOSE INTENSIFICATION; HUMAN ANTICHIMERIC ANTIBODIES; INFLIXIMAB; METHOTREXATE; PSORIASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COHORT STUDIES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894094990     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.10.059     Document Type: Article

References (25)

1. Infliximab [package insert] 2011 Janssen Biotech Inc Horsham, PA
2. P. Rutgeerts, G. Van Assche, and S. Vermeire Review article: infliximab therapy for inflammatory bowel disease-seven years on Aliment Pharmacol Ther 23 2006 451 463 (Pubitemid 43381999)
3. B. Haraoui, L. Cameron, M. Ouellet, and B. White Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response J Rheumatol 33 2006 31 36 (Pubitemid 43054276)
4. M. Chaparro, J. Panes, V. García, M. Mañosa, M. Esteve, and O. Merino et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response J Clin Gastroenterol 45 2011 113 118
5. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, and C. Guzzo et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial Lancet 366 2005 1367 1374 (Pubitemid 41443403)
6. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31.e1 31.e15
7. R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096
8. J.R. Rojas, R.P. Taylor, M.R. Cunningham, T.J. Rutkoski, J. Vennarini, and H. Jang et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys J Pharmacol Exp Ther 313 2005 578 585 (Pubitemid 40604157)
9. Y. Matsumoto, T. Maeda, R. Tsuboi, and Y. Okubo Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases J Dermatol 40 2013 1 4
10. N. Cassano, A. Puglisi Guerra, C. Malara, F. Loconsole, A. Galluccio, and M. Pezza et al. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients Int J Immunopathol Pharmacol 20 2007 647 650 (Pubitemid 47531069)
11. S. Garcês, J. Demengeot, and E. Benito-Garcia The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis Ann Rheum Dis 72 2013 1947 1955
12. K. Reich, C. Griffiths, J. Barker, S. Chimenti, E. Daudén, and A. Giannetti et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus Dermatology 217 2008 268 275
13. R.F. Van Vollenhoven, and L. Klareskog Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE Scand J Rheumatol 36 2007 418 423 (Pubitemid 350293517)
14. M.U. Rahman, I. Strusberg, P. Geusens, A. Berman, D. Yocum, and D. Baker et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis Ann Rheum Dis 66 2007 1233 1238 (Pubitemid 47309743)
15. G.G. Kaplan, C. Hur, J. Korzenik, and B.E. Sands Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Aliment Pharmacol Ther 26 2007 1509 1520 (Pubitemid 350178810)
16. R. Ariza-Ariza, F. Navarro-Sarabia, B. Hernández-Cruz, L. Rodríguez-Arboleya, V. Navarro-Compán, and J. Toyos Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis: a systematic review Rheumatology 46 2007 529 532 (Pubitemid 46344670)
17. R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, and M. Weisman et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial; ATTRACT study group Lancet 354 1999 1932 1939
18. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, and A. Carbonez et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608 (Pubitemid 36204954)
19. C.R. Mehren, and R. Gniadecki Dose-creep of infliximab during psoriasis treatment: an observational study Acta Derm Venereol 92 2012 355 357
20. G. Vena, F. Loconsole, V. Mastrandrea, R. Buquicchio, and N. Cassano Therapeutic hotline: re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab; a retrospective analysis Dermatol Ther 23 2010 199 202
21. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial Lancet 357 2001 1842 1847 (Pubitemid 32539117)
22. E.A. Brezinski, and A.W. Armstrong Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy PLoS One 7 2012 e33486
23. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542 (Pubitemid 39278071)
24. A.B. Gottlieb, U. Chaudhari, L.D. Mulcahy, S. Li, L.T. Dooley, and D.G. Baker Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis J Am Acad Dermatol 48 2003 829 835 (Pubitemid 36706213)
25. R.E. Kalb, and J. Gurske Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo J Am Acad Dermatol 53 2005 616 622 (Pubitemid 41399928)